AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
CHICAGO -- Infants born to women with polycystic ovary syndrome who are taking metformin are not significantly different from their peers in terms of length and weight over the first year of life, said Dr. Charles J. Glueck, director of the cholesterol center at Jewish Hospital, Cincinnati.
Additionally, the study of 123 live births and 119 pregnancies among 108 women found only two birth defects, a rate less than the national average, and the mothers had significantly fewer instances of gestational diabetes than in previous pregnancies, he said at the Clinical Research 2004 meeting.
"In a word, these infants were normal," Dr. Glueck said in an interview with this newspaper. "Importantly, there was no teratogenicity."
Investigators compared length and weight data from the infants in the study at birth and 3, 6, 9, and 12 months to national gender-specific data from the Centers for Disease Control and Prevention. The mothers in the study all had polycystic ovary syndrome, conceived while on metformin, and continued the drug throughout their pregnancies. Dr. Glueck said at the meeting, sponsored by the American Federation for Medical Research and the Central Society for Clinical Research.
The women were on a regiment of diet control and metformin to reverse their endocrinopathy, he said in an interview ...
Source: HighBeam Research, Women with PCOS: No increase in birth defects with metformin; Babies'...